Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer

doi:10.3969/j.issn.1673-8640.2023.09.001

Abstract

Abstract:

Lung cancer is a malignant tumor with the highest incidence and mortality in China. Liquid biopsy offers advantages such as speed，non-invasiveness and repeatability over traditional tissue biopsy，making it of value in precision medicine and treatment decision for non-small cell lung cancer（NSCLC）. This review provides a brief overview of liquid biopsy in screening，early diagnosis，treatment and prognosis evaluation and resistance surveillance. In the future，new technology of liquid biopsy needs to be further improved for sensitivity and specificity，and standardized processes and reference intervals need to be established. Prospective clinical trials also need to be conducted before its clinical transformation.

Key words: Liquid biopsy, Non-small cell lung cancer, Circulating tumor cell, Circulating tumor DNA, Extracellular vesicle

CLC Number:

R393

ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer[J]. Laboratory Medicine, 2023, 38(9): 807-811.

References 37

[1]	MEGYESFALVI Z, GAY C M, POPPER H, et al. Clinical insights into small cell lung cancer:tumor heterogeneity,diagnosis,therapy,and future directions[J]. CA Cancer J Clin, 2023.
[2]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. DOI URL
[3]	MARQUETTE C H, BOUTROS J, BENZAQUEN J, et al. Circulating tumour cells as a potential biomarker for lung cancer screening:a prospective cohort study[J]. Lancet Respir Med, 2020, 8(7):709-716. DOI URL
[4]	CHEMI F, ROTHWELL D G, MCGRANAHAN N, et al. Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse[J]. Nat Med, 2019, 25(10):1534-1539. DOI PMID
[5]	NIKANJAM M, KATO S, KURZROCK R. Liquid biopsy:current technology and clinical applications[J]. J Hematol Oncol, 2022, 15(1):131. DOI
[6]	CRISTIANO S, LEAL A, PHALLEN J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer[J]. Nature, 2019, 570(7761):385-389. DOI
[7]	FODA Z H, ANNAPRAGADA A V, BOYAPATI K, et al. Detecting liver cancer using cell-free DNA fragmentomes[J]. Cancer Discov, 2023, 13(3):616-631. DOI URL
[8]	ZHANG C, YU W, WANG L, et al. DNA methylation analysis of the SHOX2 and RASSF1A panel in bronchoalveolar lavage fluid for lung cancer diagnosis[J]. J Cancer, 2017, 8(17):3585-3591. DOI PMID
[9]	KLEIN E A, RICHARDS D, COHN A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set[J]. Ann Oncol, 2021, 32(9):1167-1177. DOI PMID
[10]	NEAL R D, JOHNSON P, CLARKE C A, et al. Cell-free DNA-based multi-cancer early detection test in an asymptomatic screening population(NHS-Galleri):design of a pragmatic,prospective randomised controlled trial[J]. Cancers(Basel), 2022, 14(19):4818.
[11]	LIANG W, CHEN Z, LI C, et al. Accurate diagnosis of pulmonary nodules using a noninvasive DNA methylation test[J]. J Clin Invest, 2021, 131(10):e145973. DOI URL
[12]	WU Y, ZHANG Y, ZHANG X, et al. Research advances for exosomal miRNAs detection in biosensing:from the massive study to the individual study[J]. Biosens Bioelectron, 2021, 177:112962. DOI URL
[13]	REIS P P, DRIGO S A, CARVALHO R F, et al. Circulating miR-16-5p,miR-92a-3p,and miR-451a in plasma from lung cancer patients:potential application in early detection and a regulatory role in tumorigenesis pathways[J]. Cancers(Basel), 2020, 12(8):2071.
[14]	PASTORINO U, BOERI M, SESTINI S, et al. Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial[J]. Ann Oncol, 2022, 33(4):395-405. DOI PMID
[15]	ETTINGER D S, WOOD D E, AISNER D L, et al. Non-small cell lung cancer,version 3.2022,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(5):497-530. DOI URL
[16]	GOLDMAN J W, NOOR Z S, REMON J, et al. Are liquid biopsies a surrogate for tissue EGFR testing?[J]. Ann Oncol, 2018, 29(Suppl 1):i38-i46. DOI URL
[17]	HENDRIKS L E, KERR K M, MENIS J, et al. Oncogene-addicted metastatic non-small-cell lung cancer:ESMO clinical practice guideline for diagnosis,treatment and follow-up[J]. Ann Oncol, 2023, 34(4):339-357. DOI URL
[18]	LI Y Z, KONG S N, LIU Y P, et al. Can liquid biopsy based on ctDNA/cfDNA replace tissue biopsy for the precision treatment of EGFR-mutated NSCLC?[J]. J Clin Med, 2023, 12(4):1438. DOI URL
[19]	ROLFO C, MACK P, SCAGLIOTTI G V, et al. Liquid biopsy for advanced NSCLC:a consensus statement from the international association for the study of lung cancer[J]. J Thorac Oncol, 2021, 16(10):1647-1662. DOI URL
[20]	BUDER A, HOCHMAIR M J, SCHWAB S, et al. Cell-free plasma DNA-guided treatment with osimertinib in patients with advanced EGFR-mutated NSCLC[J]. J Thorac Oncol, 2018, 13(6):821-830. DOI URL
[21]	YANG Y, LIU H, CHEN Y, et al. Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer:current status,challenges,and perspectives[J]. Cell Death Dis, 2023, 14(3):230. DOI
[22]	HENDRIKS L E, KERR K M, MENIS J, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer:ESMO clinical practice guideline for diagnosis,treatment and follow-up[J]. Ann Oncol, 2023, 34(4):358-376. DOI URL
[23]	GUIBERT N, DELAUNAY M, LUSQUE A, et al. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab[J]. Lung Cancer, 2018, 120:108-112. DOI PMID
[24]	PANTEL K, ALIX-PANABIÈRES C. Liquid biopsy and minimal residual disease-latest advances and implications for cure[J]. Nat Rev Clin Oncol, 2019, 16(7):409-424. DOI
[25]	SPIGEL D R, FAIVRE-FINN C, GRAY J E, et al. Five-year survival outcomes from the PACIFIC trial:durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J]. J Clin Oncol, 2022, 40(12):1301-1311. DOI URL
[26]	ABBOSH C, FRANKELL A M, HARRISON T, et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA[J]. Nature, 2023, 616(7957):553-562. DOI
[27]	XIA L, MEI J, KANG R, et al. Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer:aprospective multicenter cohort study(LUNGCA-1)[J]. Clin Cancer Res, 2022, 28(15):3308-3317. DOI URL
[28]	KASI P M. Tumor-informed versus plasma-only liquid biopsy assay in a patient with multiple primary malignancies[J]. JCO Precis Oncol, 2022, 6:e2100298.
[29]	CHEN J, YANG H, TEO A S M, et al. Genomic landscape of lung adenocarcinoma in East Asians[J]. Nat Genet, 2020, 52(2):177-186. DOI PMID
[30]	KOCH C, JOOSSE S A, SCHNEEGANS S, et al. Pre-analytical and analytical variables of label-independent enrichment and automated detection of circulating tumor cells in cancer patients[J]. Cancers(Basel), 2020, 12(2):442.
[31]	SANTINI D, BOTTICELLI A, GALVANO A, et al. Network approach in liquidomics landscape[J]. J Exp Clin Cancer Res, 2023, 42(1):193. DOI PMID
[32]	SOUZA V G P, FORDER A, BROCKLEY L J, et al. Liquid biopsy in lung cancer:biomarkers for the management of recurrence and metastasis[J]. Int J Mol Sci, 2023, 24(10):8894. DOI URL
[33]	GIMÉNEZ-CAPITÁN A, BRACHT J, GARCÍA J J, et al. Multiplex detection of clinically relevant mutations in liquid biopsies of cancer patients using a hybridization-based platform[J]. Clin Chem, 2021, 67(3):554-563. DOI URL
[34]	CHABON J J, HAMILTON E G, KURTZ D M, et al. Integrating genomic features for non-invasive early lung cancer detection[J]. Nature, 2020, 580(7802):245-251. DOI
[35]	RAZAVI P, LI B T, BROWN D N, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants[J]. Nat Med, 2019, 25(12):1928-1937. DOI PMID
[36]	WANG S, CHEN H, ZHONG J, et al. Comparative study of EGFR mutations detected in malignant pleural effusion,plasma and tumor tissue in patients with adenocarcinoma of the lung[J]. Lung Cancer, 2019, 135:116-122. DOI URL
[37]	KHANDELWAL A, SEAM R K, GUPTA M, et al. Circulating microRNA-590-5p functions as a liquid biopsy marker in non-small cell lung cancer[J]. Cancer Sci, 2020, 111(3):826-839. DOI URL